Pfizer Recognizes “Dark Side” Of Scale In R&D; No Sales Force Cuts Planned
Executive Summary
Pfizer relies on competition among research teams to help ensure that its vast R&D resources do not diminish the entrepreneurial spirit within the organization, CFO David Shedlarz told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 5 in New York City
You may also be interested in...
Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say
The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles
Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say
The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles
Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable
The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn